Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases... Show more
The RSI Indicator for SGMO moved into overbought territory on March 31, 2025. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SGMO advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .
SGMO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on March 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SGMO as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for SGMO turned negative on March 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 50-day moving average for SGMO moved below the 200-day moving average on March 13, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SGMO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SGMO entered a downward trend on March 13, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.472) is normal, around the industry mean (13.677). P/E Ratio (0.000) is within average values for comparable stocks, (64.969). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.870). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (2.288) is also within normal values, averaging (255.565).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SGMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SGMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a developer of transcription factors in the regulation of genes
Industry Biotechnology
A.I.dvisor indicates that over the last year, SGMO has been loosely correlated with AXON. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SGMO jumps, then AXON could also see price increases.
Ticker / NAME | Correlation To SGMO | 1D Price Change % | ||
---|---|---|---|---|
SGMO | 100% | -20.02% | ||
AXON - SGMO | 51% Loosely correlated | -1.68% | ||
ARRY - SGMO | 48% Loosely correlated | -4.13% | ||
BCRX - SGMO | 46% Loosely correlated | -4.58% | ||
RPRX - SGMO | 45% Loosely correlated | -0.77% | ||
AGEN - SGMO | 43% Loosely correlated | -5.94% | ||
More |